Bausch Health Companies Inc. (BHC) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-03, Bausch Health Companies Inc. (NYSE: BHC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $8.02 (-2.19% 1D, market cap $3.07B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, BHC ranks #94 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BHC carries a Roarable C+ (68/100 RQD), trailing P/E of 21.2x, gross margin of —, and ROIC of 7.6%. By comparison, TLX (Telix Pharmaceuticals Limited) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.08B) and IDYA (IDEAYA Biosciences Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -13.8%, cap $3.08B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).
Per BHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000885590), Bausch Health Companies Inc. generated $10.27B in revenue (+6.7% YoY), $157.0M in net income, and $1.00B in free cash flow against $26.37B in total assets and $20.59B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)
Capital intensity & 17.7% operating margin leave 12 pts on the table
Even with a 68/100 (C+) score, BHC faces multiple-compression risk if 21.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($6.36) or 200D SMA ($5.72) invalidates the momentum regime and cuts Target Base ($8.38) toward Bear Floor ($6.54).
Bausch Health Companies Inc. (BHC) dropped -2.19% to $8.02, trading at 78% of its 52-week range ($4.33 – $9.04). Solid steady margins (8% return on capital), mixed timing at 21x P/E—hold if owned, no rush to chase.
Yahoo! Finance Canada report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
US session market movers: NUBURU led gainers at 125.0% while GameStop's GME.W fell 48.11% among the biggest losers.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BHC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BHC. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Bausch Health Companies Inc. (BHC) ranks #94 by composite RQD confidence (68/100, grade C+) and #203 by equity capitalization ($3.07B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and — gross margin. BHC currently leads its immediate peer cohort in composite quantitative strength at 68/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BHC
ACTIVE
Bausch Health Companies Inc. | C+ | 68/100 | 21.2x | — | 7.6% | -2.19% | $3.07B | Benchmark Subject |
| TLX Telix Pharmaceuticals Limited | D | 47/100 | — | — | — | -0.55% | $3.08B | /tlx-vs-bhc → |
| IDYA IDEAYA Biosciences Inc. | E | 34/100 | — | — | -13.8% | -1.00% | $3.08B | /idya-vs-bhc → |
| DYN Dyne Therapeutics Inc. | E | 26/100 | — | — | -35.0% | +3.66% | $3.12B | /dyn-vs-bhc → |
| NRIX Nurix Therapeutics Inc. | D | 46/100 | — | — | -35.0% | -4.10% | $2.93B | /nrix-vs-bhc → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bausch Health Companies Inc. (BHC) reported GAAP revenue of $10.27B (+6.7% vs. FY2024 revenue of $9.63B , and +17.2% cumulative change since FY2023) , GAAP net income of $157.0M, operating cash flow of $1.40B, and free cash flow of $1.00B (-20.4% YoY). On the balance sheet, BHC closed FY2025 with $26.37B in total assets against $20.59B in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $10.27B | $157.0M | $1.40B | $1.00B | $26.37B | $20.59B |
| FY2024 (FY) | 2024-12-31 | $9.63B | -$46.0M | $1.60B | $1.26B | $26.52B | $18.94B |
| FY2023 (FY) | 2023-12-31 | $8.76B | -$592.0M | $1.03B | $637.9M | $10.51B | $2.46B |
As of 2026-11-03, Bausch Health Companies Inc. (NYSE: BHC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $8.02 (-2.19% 1D, market cap $3.07B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, BHC ranks #94 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BHC carries a Roarable C+ (68/100 RQD), trailing P/E of 21.2x, gross margin of —, and ROIC of 7.6%. By comparison, TLX (Telix Pharmaceuticals Limited) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.08B) and IDYA (IDEAYA Biosciences Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -13.8%, cap $3.08B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).
Per BHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000885590), Bausch Health Companies Inc. generated $10.27B in revenue (+6.7% YoY), $157.0M in net income, and $1.00B in free cash flow against $26.37B in total assets and $20.59B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.
BHC last traded at $8.02 (-2.19% on volume of 4,943,390 shares), positioning the stock +26.10% above its 50-day simple moving average ($6.36) and +40.21% above its 200-day simple moving average ($5.72). Across its 52-week range of $4.33 to $9.04, BHC sits at the 78.3% percentile with a 14-day RSI of 64.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($7.02 to $9.02).
Bausch Health Companies Inc. (BHC) earns a live Roarable RQD composite score of 68/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $8.02 (-2.19% 1D, market capitalization $3.07B).
Bausch Health Companies Inc. Is a NYSE-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..3B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Bausch Health Companies Inc. (BHC) reported $10.27B in annual revenue (up from $9.63B in FY2024, +6.7% YoY) and $157.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($8.76B revenue, -$592.0M net income) through FY2025, BHC scaled operating cash flow to $1.40B and free cash flow to $1.00B, backed by $26.37B in total assets against $20.59B in total debt.
The only sector context provided is the Health Care sector and Biotechnology: Pharmaceutical Preparations industry classification from the profile, and the beta of 0.97 from the market data, which indicates the stock has tracked broad market movement roughly in line with the market over the measurement period. Investors should note that the absence of mapped links means this brief cannot identify which suppliers, customers, or peers could transmit shocks to BHC.
Real-time company headlines, analyst actions, and sector developments for Bausch Health Companies Inc. (BHC) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Bausch Health Companies Inc. (BHC) market action, institutional positioning, and fundamental catalysts.
Long BHC at $8.20 targeting $10.82. Institutional and options positioning (18/20) plus insider cluster flow (16/20) are the strongest pillars in the rating, alongside a 28.76% price move.. Institutional whale score is 17/20 and the risk/reward vs. the $4.33 52-week low is skewed heavily in favor of bulls.
@BearTrap_Alert Shorting a 17/20 institutional whale-flow stock at $8.20 is dangerous when funds are rotating into Health Care.
I respect the product at Bausch Health Companies Inc., but the stock at $8.20 is a different story. The Altman Z-Score of 0.45 and a fundamental cash-engine score of only 8/20 signal weak financial durability behind the stock's recent rally.. FCF yield is 22.0% and RQD sits at 68/100 (C+) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).